PHAR vs ACAD

For growth investors, Pharming Group N.

V. (PHAR) is the stronger pick with 26. 9% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Pharming Group N. V. (PHAR) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 9x versus Pharming Group N. V. at 300. 0x. On forward P/E, ACADIA Pharmaceuticals Inc. is actually cheaper at 50. 9x.

Over the past 5 years, ACADIA Pharmaceuticals Inc.

(ACAD) delivered a total return of +7. 1%, compared to -9. 1% for Pharming Group N. V. (PHAR). Over 10 years, the gap is even starker: ACAD returned -22. 9% versus PHAR's -28. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pharming Group N.

V. (PHAR) is the lower-risk stock at 1. 22β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 3% more volatile than PHAR relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 42% for Pharming Group N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pharming Group N.

V. (PHAR) is pulling ahead at 26. 9% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Pharming Group N. V. grew EPS 123. 5% year-over-year, compared to 68. 4% for ACADIA Pharmaceuticals Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus 0. 8% for Pharming Group N. V. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus 5. 1% for PHAR. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACADIA Pharmaceuticals Inc.

(ACAD) trades at 50. 9x forward P/E versus 59. 2x for Pharming Group N. V. — 8. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHAR: 222. 3% to $38. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Pharming Group N.

V. (PHAR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Both have compounded well over 10 years (PHAR: -28. 1%, ACAD: -22. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PHAR is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.